News Headlines Article

Stanford cancer spinout lands big biotech deal
San Francisco Business Times

A young Stanford University drug-discovery spinout, aimed at getting unprecedented closeup views of tumor cells, will get $45 million upfront in a potential $485 million deal with Celgene Inc. Quanticel Pharmaceuticals Inc., which CEO Stephen Kaldor has described as providing in “exquisite detail” individual cells from a tumor sample, disclosed the deal Monday. It said Celgene (NASDAQ: CELG) also will take equity in the San Francisco company and have an exclusive option to buy Quanticel.